Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.62 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099283 | 1.00 | CHRNA7 (0.62) | CHRNA7USP30PRKAA2HTR3EHTR3B | |
| SCHEMBL6100787 | 0.95 | CHRNA7 (0.55) | CHRNA7USP30PRKAA2HTR3EHTR3B | |
| SCHEMBL6102090 | 0.90 | CHRNA7 (0.62) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6102094 | 0.90 | CHRNA7 (0.62) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6102041 | 0.85 | CHRNA7 (0.55) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6098148 | 0.85 | CHRNA7 (0.65) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6098144 | 0.85 | CHRNA7 (0.65) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6101100 | 0.85 | CHRNA7 (0.65) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6101112 | 0.85 | CHRNA7 (0.65) | CHRNA7USP30HTR3EHTR3BHTR3A | |
| SCHEMBL6100531 | 0.83 | CHRNA7 (0.61) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885USP30 3403/4885PRKAA2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.